Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 9/20 | 0.43 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | PIKFYVE | Q9Y2I7 | 3/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536274 | 0.81 | TTBK1 (0.48) | TTBK1CHUKMAP3K14PIKFYVEPAK4 | |
| SCHEMBL24816245 | 0.78 | NOS3 (0.43) | TTBK1CHUKNOS3NOS1NOS2 | |
| SCHEMBL24806305 | 0.78 | TTBK1 (0.41) | TTBK1CHUKMAP3K14PIKFYVEPAK4 | |
| SCHEMBL23021937 | 0.78 | RECQL (0.43) | TTBK1CHUKMAP3K14 | |
| SCHEMBL22387458 | 0.76 | TTBK1 (0.41) | TTBK1CCR1CCR5CCR8CHUK | |
| SCHEMBL30390040 | 0.75 | UHRF1 (0.41) | UHRF1CCR1CCR5CCR8KDM4E | |
| SCHEMBL1201922 | 0.74 | GRM5 (0.49) | — | |
| SCHEMBL16289228 | 0.73 | UHRF1 (0.46) | UHRF1CCR1CCR5CCR8KDM4E | |
| SCHEMBL2716821 | 0.72 | CCR1 (0.45) | UHRF1CCR1CCR5CCR8KDM4E | |
| SCHEMBL739784 | 0.70 | GRM5 (0.45) | TTBK1CHUKKDM4EMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271659-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-7176314-B2 | IkB kinases (IKK) enzyme inhibitors, a imidazole-5-yl-quinoline derivatives compounds | AMGEN, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20030181472-A1 | Inflammation modulators | TULARIK INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003048152-A2 | INFLAMMATION MODULATORS | TULARIK INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181472-A1 | Inflammation modulators | NFATC1, NFKBIA, RELA | TTBK1 1645/4885UHRF1 2277/4885CCR1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.